Professor Brett Neilan is a molecular biologist and an expert in the study of microbial diversity and their chemistries. The main topic of his work is the genetics of toxic cyanobacteria (blue-green algae). His research has led to an understanding of the biochemical pathways that are responsible for the production of their toxins.
He obtained his PhD in microbial and molecular biology from University of New South Wales. Prior to his PhD training, Brett obtained a BAppSc in biomedical science at the University of Technology, Sydney and then worked as a biotechnologist, medical researcher, and forensic biologist.
His postdoctoral position as an Alexander von Humboldt Fellowship in Berlin was on complex biosynthesis genetics. The continuation of this early work and a NASA internship at Stanford University has become the basis for current studies regarding the search for microbial natural products in novel environments, including in symbiotic relationships with plants and under the extreme conditions of Antarctica and Australian deserts.
Previously a Federation Fellow for the Australian Research Council at the University of New South Wales, Brett is now the Global Innovation Chair in Biotechnology at the University of Newcastle and studies the mechanisms responsible for the complex biosynthesis of a range of biomaterials and pharmacologically active compounds to assist in the design and synthesis of novel products in a photosynthetic bioreactor.
Matt has worked in the medical and clinical research industry since 2000, with experience working for multinational companies in Asia Pacific, Europe and the USA.
In 2015 he was one of the original founders who sought and attained capital funding for a new company, Paratus Clinical of which he is now Chief Commercial Officer.
Paratus Clinical sites run studies on behalf of mainly commercial ‘sponsors’ in Primary and Specialist care in a growing network of sites, across the Eastern states of Australia.
With a background in Biotechnology and Business (Commerce), my experience crosses the translational research pipeline (medical/scientific) from laboratory research to clinical trials. I am currently involved in overseeing and coordinating support for research across NSW Health Pathology, including governance, strategy and intellectual property.
NSW Health Pathology is our State’s public pathology service provider operating >200 collection centres and 60 laboratories across the State. We provide clinical testing services to patients referred to us from hospitals, general practices or other referral centres and conduct our own research into new diagnostic tests and technologies. In collaboration with our research communities (University, government and commercial) we also provide a multitude of clinical and RoU (Research only use) tests across the areas of microbiology, anatomical pathology, clinical chemistry, immunology, and haematology and are in the unique positioned to have an ever expanding innovative point of care technology, genomics and forensic science services.
While NSW Health Pathology spans across all of NSW, our support to regional initiatives and our ability to provide access to a unique pool of experienced clinicians and scientists and associated pathological data means we are able to collaborate on advancements in medical technologies and pharmaceuticals. I would love to have a chat if you have any questions about research in general or how NSW Health Pathology may be able to assist you and your medtech idea!
Darran Leyden is the Managing Director of Whiteley Corporation who are a global leader in developing and manufacturing novel Infection Prevention products. Whiteley are an Australian owned company based in the Hunter.
Darran has been involved in a number of collaborative research projects with Australian and International Universities leading to numerous patents and the commercialization of products to global Healthcare markets. He has extensive experience in Export markets and has been a Director of Whiteley Corporation NZ since 2014.
His education includes a Bachelor of Science and a Master Of Business (Merit) from Newcastle University and he is a keen advocate of supporting Advanced Manufacturing, MedTeCCH, STEM and Rugby within the Hunter region.